Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Aminodiol HIV protease inhibitors. Synthesis and structure-activity relationships of P1/P1' compounds: correlation between lipophilicity and cytotoxicity.

Chen P, Cheng PT, Alam M, Beyer BD, Bisacchi GS, Dejneka T, Evans AJ, Greytok JA, Hermsmeier MA, Humphreys WG, Jacobs GA, Kocy O, Lin PF, Lis KA, Marella MA, Ryono DE, Sheaffer AK, Spergel SH, Sun CQ, Tino JA, Vite G, Colonno RJ, Zahler R, Barrish JC.

J Med Chem. 1996 May 10;39(10):1991-2007.

PMID:
8642558
2.

Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.

Rose RE, Gong YF, Greytok JA, Bechtold CM, Terry BJ, Robinson BS, Alam M, Colonno RJ, Lin PF.

Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1648-53.

3.

Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor.

Patick AK, Rose R, Greytok J, Bechtold CM, Hermsmeier MA, Chen PT, Barrish JC, Zahler R, Colonno RJ, Lin PF.

J Virol. 1995 Apr;69(4):2148-52.

4.

Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease.

Bechtold CM, Patick AK, Alam M, Greytok J, Tino JA, Chen P, Gordon E, Ahmad S, Barrish JC, Zahler R, et al.

Antimicrob Agents Chemother. 1995 Feb;39(2):374-9.

5.

Aminodiol HIV protease inhibitors. 1. Design, synthesis, and preliminary SAR.

Barrish JC, Gordon E, Alam M, Lin PF, Bisacchi GS, Chen P, Cheng PT, Fritz AW, Greytok JA, Hermsmeier MA.

J Med Chem. 1994 Jun 10;37(12):1758-68.

PMID:
8021916

Supplemental Content

Loading ...
Support Center